Abstract |
Aim: To evaluate real-world clinical outcomes of radium-223 or alternative novel hormonal therapy (NHT) following first-line NHT for metastatic castration-resistant prostate cancer (mCRPC). Patients & methods: Retrospective analysis of the US Flatiron database (ClinicalTrials.gov identifier: NCT03896984). Results: In the radium-223 cohort (n = 120) versus the alternative NHT cohort (n = 226), proportionally more patients had prior symptomatic skeletal events and bone-only metastases, and first-line NHT duration was shorter. Following second-line therapy, 49 versus 39% of patients received subsequent life-prolonging therapy; of these, 47 versus 76% received taxane. Median overall survival was 10.8 versus 11.2 months. Conclusion: Real-world patients with mCRPC had similar median overall survival following second-line radium-223 or alternative NHT after first-line NHT. Many patients received subsequent therapy, with less taxane use after radium-223.
|
Authors | Oliver Sartor, Daniel George, Bertrand Tombal, Neeraj Agarwal, Celestia S Higano, Cora N Sternberg, Kurt Miller, XiaoLong Jiao, Helen Guo, Per Sandström, Amanda Bruno, Frank Verholen, Fred Saad, Neal Shore |
Journal | Future oncology (London, England)
(Future Oncol)
Vol. 18
Issue 1
Pg. 35-45
(Jan 2022)
ISSN: 1744-8301 [Electronic] England |
PMID | 34636627
(Publication Type: Journal Article)
|
Chemical References |
- Benzamides
- Nitriles
- Phenylthiohydantoin
- Radium-223
- enzalutamide
- Abiraterone Acetate
- Prednisone
- Radium
|
Topics |
- Abiraterone Acetate
(administration & dosage)
- Aged
- Aged, 80 and over
- Benzamides
(administration & dosage)
- Bone Neoplasms
(secondary)
- Humans
- Male
- Middle Aged
- Nitriles
(administration & dosage)
- Phenylthiohydantoin
(administration & dosage)
- Prednisone
(administration & dosage)
- Prostatic Neoplasms, Castration-Resistant
(mortality, pathology, therapy)
- Radium
(therapeutic use)
- Retrospective Studies
|